LUCD Q2 EPS Estimate Boosted by Ascendiant Capital Markets

Lucid Diagnostics Inc. (NASDAQ:LUCD) – Stock analysts at Ascendiant Capital Markets upped their Q2 2026 earnings per share (EPS) estimates for Lucid Diagnostics in a report issued on Friday, June 5th. Ascendiant Capital Markets analyst E. Woo now expects that the company will earn ($0.05) per share for the quarter, up from their previous forecast of ($0.06). Ascendiant Capital Markets currently has a “Buy” rating and a $9.25 target price on the stock. The consensus estimate for Lucid Diagnostics’ current full-year earnings is ($0.23) per share. Ascendiant Capital Markets also issued estimates for Lucid Diagnostics’ Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.23) EPS, Q1 2027 earnings at ($0.05) EPS, Q2 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.18) EPS.

Lucid Diagnostics (NASDAQ:LUCD) last announced its earnings results on Thursday, May 14th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $1.26 million during the quarter, compared to analyst estimates of $1.38 million.

A number of other research analysts have also recently commented on LUCD. Maxim Group reduced their target price on shares of Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Wednesday, May 6th. Needham & Company LLC reissued a “buy” rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a research report on Thursday, March 26th. Wall Street Zen upgraded Lucid Diagnostics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, BTIG Research reaffirmed a “buy” rating and set a $2.50 target price on shares of Lucid Diagnostics in a research report on Friday, May 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $4.19.

Lucid Diagnostics Price Performance

Shares of NASDAQ:LUCD opened at $0.96 on Monday. The company has a market capitalization of $195.09 million, a price-to-earnings ratio of -2.04 and a beta of 1.08. The company has a 50 day moving average of $1.09 and a two-hundred day moving average of $1.17. Lucid Diagnostics has a 52-week low of $0.90 and a 52-week high of $1.63.

Insider Buying and Selling at Lucid Diagnostics

In related news, Director Dennis Matheis bought 245,000 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $1.00 per share, with a total value of $245,000.00. Following the transaction, the director owned 1,033,443 shares of the company’s stock, valued at approximately $1,033,443. This trade represents a 31.07% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Lucid Diagnostics

A number of hedge funds have recently bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new stake in Lucid Diagnostics in the first quarter valued at about $39,000. Goldman Sachs Group Inc. lifted its holdings in Lucid Diagnostics by 35.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock worth $129,000 after buying an additional 22,727 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Lucid Diagnostics by 420.3% in the 2nd quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock worth $1,814,000 after acquiring an additional 1,274,194 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Lucid Diagnostics by 71,026.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock worth $38,000 after acquiring an additional 32,672 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new stake in shares of Lucid Diagnostics in the 2nd quarter valued at approximately $97,000. 74.01% of the stock is currently owned by institutional investors and hedge funds.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.